These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 597712)

  • 1. Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma.
    Bishop MC; Fellows GJ
    Br J Urol; 1977; 49(7):711-6. PubMed ID: 597712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of calcitonin and hexestrol on urinary excretion of hydroxyproline in a patient with prostatic cancer and bone metastases.
    Matsushita Y; Hasegawa K; Sugimura R; Otomo S; Morii H
    Endocrinol Jpn; 1974 Apr; 21(2):109-13. PubMed ID: 4408206
    [No Abstract]   [Full Text] [Related]  

  • 3. Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer.
    Hopkins SC; Nissenkorn I; Palmieri GM; Ikard M; Moinuddin M; Soloway MS
    J Urol; 1983 Feb; 129(2):319-23. PubMed ID: 6834497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer.
    Rinsho K; Aoyagi K
    Tohoku J Exp Med; 1982 Aug; 137(4):461-2. PubMed ID: 7123546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
    Gielen F; Dequeker J; Drochmans A; Wildiers J; Merlevede M
    Br J Cancer; 1976 Sep; 34(3):279-85. PubMed ID: 974001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum osteocalcin concentration in patients with prostatic cancer.
    Francini G; Bigazzi S; Leone V; Gennari C
    Am J Clin Oncol; 1988; 11 Suppl 2():S83-7. PubMed ID: 3266542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
    J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases.
    Heller W; Harzmann R; Bichler KH; Schmidt K
    Curr Probl Clin Biochem; 1979; (9):249-56. PubMed ID: 446076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Urinary and serum hydroxyproline in the diagnosis of bone metastases of prostatic cancer].
    Gasser AB; Jeannet C; Depierre D; Courvoisier B
    Schweiz Med Wochenschr; 1981 Feb; 111(8):246-51. PubMed ID: 7233140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
    Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
    Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary hydroxyproline excretion in patients with cancer.
    Guzzo CE; Pachas WN; Pinals RS; Krant MJ
    Cancer; 1969 Aug; 24(2):382-7. PubMed ID: 5796782
    [No Abstract]   [Full Text] [Related]  

  • 12. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer (II): Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and tumor markers in blood and urine].
    Nemoto S; Rinsho K
    Nihon Hinyokika Gakkai Zasshi; 1984 Jan; 75(1):53-8. PubMed ID: 6539837
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
    Unni Mooppan MM; Kim H; Wang JC; Tobin MS; Wax SH
    Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone scanning and plasma phosphatases in carcinoma of the prostate.
    O'Donoghue EP; Constable AR; Sherwood T; Stevenson JJ; Chisholm GD
    Br J Urol; 1978 May; 50(3):172-7. PubMed ID: 753455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary hydroxyproline and plasma mucoprotein as an indication of the presence of bone metastases.
    Basu TK; Donaldson D; Williams DC
    Oncology; 1974; 30(3):197-203. PubMed ID: 4459734
    [No Abstract]   [Full Text] [Related]  

  • 16. Urinary hydroxyproline excretion in early and advanced breast cancer-a sequential study.
    Cuschieri A
    Br J Surg; 1973 Oct; 60(10):800-3. PubMed ID: 4748385
    [No Abstract]   [Full Text] [Related]  

  • 17. Total and nondialyzable hydroxyproline excretion in Stage D2 prostate cancer.
    Hopkins SC; Palmieri GM; Niell HB; Moinuddin M; Soloway MS
    Cancer; 1984 Jan; 53(1):117-21. PubMed ID: 6689994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer].
    Rinsho K
    Nihon Hinyokika Gakkai Zasshi; 1983 Jan; 74(1):76-80. PubMed ID: 6191064
    [No Abstract]   [Full Text] [Related]  

  • 19. URINARY HYDROXYPROLINE EXCRETION IN METASTATIC CANCER OF BONE.
    Platt WD; Doolittle LH; Hartshorn JW
    N Engl J Med; 1964 Aug; 271():287-90. PubMed ID: 14161766
    [No Abstract]   [Full Text] [Related]  

  • 20. Bone imaging and serum phosphatases in prostatic carcinoma.
    Bishop MC; Hardy JG; Taylor MC; Wastie ML; Lemberger RJ
    Br J Urol; 1985 Jun; 57(3):317-24. PubMed ID: 4005501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.